Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND: All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity. METHODS: We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with ATRA plus arsenic trioxide in patients with APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter). Patients were randomly assigned to receive either ATRA plus arsenic trioxide for induction and consolidation therapy or standard ATRA-idarubicin induction therapy followed by three cycles of consolidation therapy with ATRA plus chemotherapy and maintenance therapy with low-dose chemotherapy and ATRA. The study was designed as a noninferiority trial to show that the difference between the rates of event-free survival at 2 years in the two groups was not greater than 5%. RESULTS: Complete remission was achieved in all 77 patients in the ATRA-arsenic trioxide group who could be evaluated (100%) and in 75 of 79 patients in the ATRA-chemotherapy group (95%) (P=0.12). The median follow-up was 34.4 months. Two-year event-free survival rates were 97% in the ATRA-arsenic trioxide group and 86% in the ATRA-chemotherapy group (95% confidence interval for the difference, 2 to 22 percentage points; P<0.001 for noninferiority and P=0.02 for superiority of ATRA-arsenic trioxide). Overall survival was also better with ATRA-arsenic trioxide (P=0.02). As compared with ATRA-chemotherapy, ATRA-arsenic trioxide was associated with less hematologic toxicity and fewer infections but with more hepatic toxicity. CONCLUSIONS: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL. (Funded by Associazione Italiana contro le Leucemie and others; ClinicalTrials.gov number, NCT00482833.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Self-citationCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Self-citationShen, Z.-X., Chen, G.-Q., Ni, J.-H., Li, X.-S., Xiong, S.-M., Qiu, Q.-Y., Zhu, J., Tang, W., Sun, G.-L., Yang, K.-Q., et al. (1997) · Blood · doi:10.1182/blood.v89.9.3354 · Cited by 1,428
Gabert, J., Beillard, E., van der Velden, V. H. J., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J. M., Cavé, H., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403135 · Cited by 1,284
Acute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z.-Y., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,277
van Dongen, J., Macintyre, E., Gabert, J., Delabesse, E., Rossi, V, Saglio, G., Gottardi, E., Rambaldi, A., Dotti, G., Griesinger, F., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401592 · Cited by 1,169
Self-citationSanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationUnited States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3852 · Cited by 826 · cited 1×
“A genetic diagnosis could be established by detection of the PML-RARA fusion gene by means of reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay,28,29 demonstration of the t(15;17) translocation by means of conventional karyotyping or fluorescence in situ hybridization (FISH),30 or evidence of a microspeck…”
Research works printed but not linked: 3
- Zhang P, 1996, Chin J Hematol, 17, 58
- Sanz MA, 2000, Blood, 96, 1247
- Grimwade D, 2000, Blood, 96, 1297
Cited by
Items 301–400 of 1,000
Distance-based clustering challenges for unbiased benchmarking studies
Thrun, M. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-98126-1 · Cited by 50
Torque teno mini virus as a cause of childhood acute promyelocytic leukemia lacking PML/RARA fusion
Astolfi, A., Masetti, R., Indio, V., Bertuccio, S. N., Messelodi, D., Rampelli, S., Leardini, D., Carella, M., Serravalle, S., Libri, V., et al. (2021) · Blood · doi:10.1182/blood.2021011677 · Cited by 39
Coombs, C. C., DeAngelis, L. M., Feusner, J. H., Rowe, J. M., & Tallman, M. S. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.11.018 · Cited by 39
Käyser, S., Rahmé, R., Martínez‐Cuadrón, D., Ghiaur, G., Thomas, X., Sobas, M., Guerci‐Bresler, A., Garrido, A., Pigneux, A., Gil, C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0758-4 · Cited by 38
Self-citationDai, B., Wang, F., Wang, Y., Zhu, J., Li, Y., Zhang, T., Zhao, L., Wang, L., Gao, W., Li, J., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01139-8 · Cited by 43
“Although the therapeutic strategy of As2O3 combined with ATRA highly improves the prognosis of APL, 10–20% of patients are refractory or relapse after treatment [5, 7, 10, 11].”
BackgroundHermsen, J., & Hambley, B. C. (2023) · Cancers · doi:10.3390/cancers15133477 · Cited by 42
The Warburg effect: The hacked mitochondrial-nuclear communication in cancer
Jiang, H., & Ye, J. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.03.006 · Cited by 47
Efficace, F., Cottone, F., Sommer, K., Kieffer, J. M., Aaronson, N. K., Fayers, P. M., Grøenvold, M., Caocci, G., Lo‐Coco, F., Gaïdano, G., et al. (2019) · Value in Health · doi:10.1016/j.jval.2019.06.004 · Cited by 48
Self-citationGasparovic, L., Weiler, S., Higi, L., & Burden, A. M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103342 · Cited by 37
“Platzbecker, 2016 [51]; LoCoco, 2013 [52] 266 48.”
Retinoic acid signaling in development and differentiation commitment and its regulatory topology
Wu, D., Khan, F. A., Zhang, K., Pandupuspitasari, N. S., Negara, W., Guan, K., Sun, F., & Huang, C. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110773 · Cited by 43
How I treat children and adolescents with acute promyelocytic leukaemia
Abla, O., & Ribeiro, R. C. (2013) · British Journal of Haematology · doi:10.1111/bjh.12584 · Cited by 38
“…German–Austrian Acute Myeloid Leukemia Study Group [AMLSG]) in adults with standardrisk APL achieved a 2-year EFS of 97% after ATO+ATRA vs. 86 7% after ATRA plus chemotherapy; the latter group also experienced greater toxicity and more frequent early death and recurrence (Lo-Coco et al, 2013).”
BackgroundHu, S., Ueda, M., Stetson, L., Ignatz-Hoover, J., Moreton, S., Chakrabarti, A., Xia, Z., Karan, G., de Lima, M., Agrawal, M. K., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0566 · Cited by 38
“Differentiation therapy has demonstrated remarkable clinical efficacy for a small subset of AML patients with APL reinforcing its potential as an attractive therapeutic strategy for this disease (2).”
BackgroundCreutzig, U., Dworzak, M. N., Bochennek, K., Faber, J., Flotho, C., Graf, N. M., Kontny, U., Rössig, C., Schmid, I., von Stackelberg, A., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26461 · Cited by 37
Bruserud, Ø., Aasebø, E., Hernandez-Valladares, M., Tsykunova, G., & Reikvam, H. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1356818 · Cited by 39
Ravandi, F., Koumenis, I. L., Johri, A. R., Tallman, M. S., Roboz, G. J., Strickland, S. A., Garcia‐Manero, G., Borthakur, G. M., Naqvi, K. Z., Meyer, M. A., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.229583 · Cited by 38
“Recently, two large randomized trials have shown that the combination of ATRA and IV ATO for induction is superior to ATRA + chemotherapy in the treatment of APL patients with standard-risk disease.(14,15) Moreover, longterm follow-up of these patients showed that patients treated with ATRA + IV ATO had a significantl…”
BackgroundResultAlbano, F., Zagaria, A., Anelli, L., Coccaro, N., Tota, G., Brunetti, C., Minervini, C. F., Impera, L., Minervini, A., Cellamare, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3773 · Cited by 36
Self-citationFan, X., Chen, X.-Y., Liu, Y., Zhong, H., Jiang, F., & Liu, Y. (2016) · Scientific Reports · doi:10.1038/srep29865 · Cited by 36
Hore, T. A. (2017) · Epigenomics · doi:10.2217/epi-2017-0021 · Cited by 38
Anxiety and depression predict unfavorable survival in acute myeloid leukemia patients
Ding, T., Wang, X., Fu, A., Xu, L., & Lin, J. (2019) · Medicine · doi:10.1097/md.0000000000017314 · Cited by 36
“Therefore, the prognosis of AML has been improved, but remains poor in recent years,with a 5-year survival rate being approximately under 50% in younger patients and even worse in elderly patients.([4,5]) The substantial mental distress caused by disease burden (such as estimated poor prognosis) has resulted in an inc…”
BackgroundHemorrhage in acute promyelocytic leukemia: Can it be predicted and prevented?
Naymagon, L., & Mascarenhas, J. O. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106356 · Cited by 37
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
Fenwarth, L., Fournier, É., Cheok, M. H.-C., Boyer, T., Gonzales, F., Castaigné, S., Boissel, N., Lambert, J., Dombret, H., Preudhomme, C., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165626 · Cited by 36
“The standard of care for APL treatment relies on all-trans retinoic acid (ATRA) plus or minus arsenic trioxide (ATO)-based regimen [62,63].”
BackgroundAdvancing Leukemia Diagnostics: Role of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia
Haferlach, T. (2020) · Hematology Reports · doi:10.4081/hr.2020.8957 · Cited by 45
Non‐genetic heterogeneity, altered cell fate and differentiation therapy
Lewis, A. C., & Kats, L. M. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012670 · Cited by 36
Gill, H., Raghupathy, R., Lee, C. Y. Y., Yung, Y., Chu, H.-T., Ni, M. Y., Xiao, X., Flores, F. P., Yim, R., Lee, P., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10612-z · Cited by 40
“Whether the use of a chemotherapy-free strategy in APL [8] may reduce second cancers warrants further investigations.”
BackgroundAcute Promyelocytic Leukemia: A Summary
Ryan, M. (2018) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2018.9.2.4 · Cited by 40
“When compared with those patients who received ATRA plus anthracycline-based regimens, the event-free survival rates were 97% in the ATRA/ATO group vs. 85% in the ATRA/chemotherapy group (Lo-Coco et al., 2013).”
BackgroundMethodResultInfluentialVarying responses of PML-RARA with different genetic mutations to arsenic trioxide
Liu, J., Zhu, H., Jiang, H., Jiang, Q., & Huang, X. (2015) · Blood · doi:10.1182/blood-2015-04-637678 · Cited by 37
He, H., Duo, H., Hao, Y., Zhang, X., Zhou, X., Zeng, Y., Li, Y., & Li, B. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106671 · Cited by 36
Differentiation Syndrome in Acute Leukemia: APL and Beyond
Woods, A. C., & Norsworthy, K. J. (2023) · Cancers · doi:10.3390/cancers15194767 · Cited by 40
Acute Myeloid Leukemia With Recurrent Cytogenetic Abnormalities
Foucar, K. K., & Anastasi, J. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpi9c8uilyqtns · Cited by 35
Li, L., Bonneton, F., Chen, X., & Laudet, V. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.10.028 · Cited by 38
“Currently, almost 100,000 TCM preparations using 11,000 kinds of herbs, 300 minerals and animal extracts are used in China to treat more than 3700 diseases (Qiu, 2007).”
InfluentialMa, Y., Liu, L., Jin, J., & Lou, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158760 · Cited by 35
“ATRA, all-trans retinoic acid; ATO arsenic trioxide; IDA, idarubicin; MTX, methotrexate; 6-MP, 6-mercaptopurine; GO, gemtuzumab ozogamicin. a AIDA schedule:According to the standard all-trans retinoic acid and idarubicin based therapy. b Based on the median time to complete remission. doi:10.1371/journal.pone.0158760.…”
BackgroundMethodInfluentialGutiérrez, A., & Kentsis, A. (2018) · British Journal of Haematology · doi:10.1111/bjh.15129 · Cited by 36
Bolis, M., Paroni, G., Fratelli, M., Vallerga, A., Guarrera, L., Zanetti, A., Kurosaki, M., Garattini, S. K., Gianni’, M., Lupi, M., et al. (2020) · Cancers · doi:10.3390/cancers12051169 · Cited by 40
“All-trans retinoic acid (ATRA), the active metabolite of vitamin A, is used in the treatment of acute promyelocytic leukemia, with remarkable results [1,2].”
Acute Myeloid Leukemia: Past, Present, and Prospects for the Future
Short, N. J., & Ravandi, F. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.02.007 · Cited by 34
“The impressive clinical efficacy of chemotherapy-free regimens for APL also raise questions as to what extent the development of targeted therapy in AML might reduce or even eliminate the need for chemotherapy in certain subgroups.(37,38)”
BackgroundAdès, L., Thomas, X., Guerci‐Bresler, A., Raffoux, E., Spertini, O., Vey, N., Marchand, T., Récher, C., Pigneux, A., Girault, S., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.198614 · Cited by 34
“In particular, it was shown in two large randomized trials that the combination of ATO and ATRA without chemotherapy was at least equal and, with longer term follow-up, even superior to ATRA plus chemotherapy combinations in standard-risk APL.(9,10,11) In high-risk APL, ATO plus ATRA combinations, with very limited ad…”
MethodApplication of precision medicine in clinical routine in haematology—Challenges and opportunities
Wästerlid, T., Cavelier, L. B., Haferlach, C., Konopleva, M. Y., Fröhling, S., Östling, P., Bullinger, L., Fioretos, T., & Smedby, K. E. E. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13508 · Cited by 38
“…therapy for molecular subsets were, for a long time, limited to the use of all-trans retinoic acid/arsenic trioxide in acute promyelocytic leukemia [66] and subsequent recognition of the benefits of anti-CD33 antibody-drug conjugate gemtuzumab ozogamicin (GO) in core-binding factor leukaemias [67],…”
High ΔNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia
Lucena-Araujo, A. R., Kim, H. T., Thomé, C. H., Jácomo, R. H., Melo, R. A. M., Bittencourt, R., Pasqüini, R., Pagnano, K. B. B., Gloria, A. B. F., Chauffaille, M. D. L., et al. (2015) · Blood · doi:10.1182/blood-2015-01-623330 · Cited by 39
Self-citationTREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice
Xie, X., Zhang, W., Xiao, M., Wei, T., Qiu, Y., Qiu, J., Wang, H., Qiu, Z., Zhang, S., Pan, Y., et al. (2023) · Blood · doi:10.1182/blood.2022018619 · Cited by 41
Mi, J.-Q., Chen, S., Zhou, G., Yan, X., & Chen, Z. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12376 · Cited by 37
Falchi, L., Verstovšek, S., Ravandi‐Kashani, F., & Kantarjian, H. M. (2015) · Cancer · doi:10.1002/cncr.29852 · Cited by 33
“It is noteworthy that the ATRA 1 ATO combination was associated with less hematologic toxicity and fewer infections but with greater hepatotoxicity.(42) That trial established ATRA 1 ATO as the standard of care for patients with newly diagnosed, nonhigh-risk APL.”
BackgroundMinamiguchi, H., Fujita, H., Atsuta, Y., Asou, N., Sakura, T., Ueda, Y., Sawa, M., Dobashi, N., Taniguchi, Y., Suzuki, R., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04245-6 · Cited by 35
Hu, L., Liu, J., Ye, M., Zheng, H., Ding, C., Wang, H., Charwudzi, A., Li, M., Li, J., Zhai, Z., et al. (2020) · RNA Biology · doi:10.1080/15476286.2020.1854520 · Cited by 33
“Thus, the application of ATRA has made great progress in the treatment and prognosis of the most dangerous AML subtype, acute promyelocytic leukaemia (APL), also known as AML-M3 [6].”
BackgroundGurnari, C., Voso, M. T., Girardi, K., Mastronuzzi, A., & Strocchio, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020642 · Cited by 32
“In the seminal phase three Italian-German study APL0406, the combination of ATRA and ATO led to impressive cure rates and survival outcomes in SR adult patients with APL, paving the way for totally chemotherapy-free protocols [62].”
BackgroundReville, P. K., & Kadia, T. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.619085 · Cited by 41
“The current standard of care for most patients with AML achieving a CR with induction and consolidation is observation without maintenance therapy, with the exception of acute promyelocytic leukemia where maintenance arsenic trioxide and retinoic acid have shown clear benefit (19, 20).”
BackgroundThe Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away
Nagai, Y., & Ambinder, A. J. (2023) · Cancers · doi:10.3390/cancers15143535 · Cited by 36
“More recently, dual-targeted therapy consisting of ATRA and ATO achieved superior event-free survival (EFS) and overall survival (OS) compared to ATRA plus chemotherapy for patients with low-to-intermediate risk of APL in the phase 3 trial (APL0406) [32,33] (Table 1).”
BackgroundAcute promyelocytic leukemia during pregnancy: a systematic analysis of outcome
Verma, V., Giri, S., Manandhar, S., Pathak, R., & Bhatt, V. R. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1065977 · Cited by 33
Zhang, X., Yang, X., Sun, C., Hu, B., Sun, Y., Huang, X., Wang, Z., He, Y., Zeng, H., Qiu, S., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.06.014 · Cited by 33
Gill, H., Yim, R., Kumana, C. R., Tse, E., & Kwong, Y. (2020) · Cancer · doi:10.1002/cncr.32937 · Cited by 33
“Platelet count, ×10(9)/L, median (range) 88 (9-280) Clinicopathologic features during reinduction at R1 Peak leukocyte count >10 × 10(9)/L, n (%) 1 (5.”
BackgroundInfluentialKumana, C. R., Mak, R., Kwong, Y., & Gill, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01294 · Cited by 32
“As2O3-ATRA treatment, the latter being associated with transaminitis that occurred in 44–71% of patients (12, 34, 35).”
BackgroundResultSun, J., Mao, F., Liu, C. X., Zhang, F., Jiang, D., Guo, W., Huo, L., Zhou, L., Lau, W. Y., Shi, J., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01604-3 · Cited by 36
Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges
Senapati, J., Kadia, T. M., Daver, N. G., Dinardo, C. D., Borthakur, G. M., Ravandi, F., & Kantarjian, H. M. (2025) · Cancer · doi:10.1002/cncr.35806 · Cited by 33
“…an ATRA–anthracycline–based approach was later established in at least three RCTs from Italy and Germany (APL0406 trial; low/intermediate–risk APL), 146,147 the United Kingdom (AML MRC 17 trial; used higher doses but less frequent ATO dosing and included all - risk patients), 148 and China (APL15…”
Song, J., Zhao, Z., Fan, X., Chen, M., Cheng, X., Zhang, D., Wu, F., Ying, X., & Ji, J. (2016) · Oncotarget · doi:10.18632/oncotarget.12041 · Cited by 32
“Arsenic trioxide (ATO) is an effective anticancer drug used in patients with relapsed acute promyelocytic leukemia (APL), and is intensively investigated for treatment of other tumors [6, 7].”
BackgroundTargeting cancer energy metabolism: a potential systemic cure for cancer
Kim, S. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01115-2 · Cited by 35
Purification of crude As2O3 recovered from antimony smelting arsenic-alkali residue
Long, H., Huang, X.-Z., Zheng, Y., Peng, Y.-L., & He, H. (2020) · Process Safety and Environmental Protection · doi:10.1016/j.psep.2020.04.015 · Cited by 33
Aldoss, I., Mark, L., Vrona, J., Ramezani, L., Weitz, I. C., Mohrbacher, A. M., & Douer, D. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2124-y · Cited by 32
Chau, D., Ng, K. K. M., Chan, T. S. Y., Cheng, Y. Y., Fong, B. M.-W., Tam, S., Kwong, Y., & Tse, E. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0143-3 · Cited by 33
“With the use of ATRA and chemotherapy, complete remission (CR) rates of over 90% can be achieved in newly diagnosed APL.”
BackgroundInfluentialThe Novel Arsenical Darinaparsin Is Transported by Cystine Importing Systems
Garnier, N. M., Redstone, G. G. J., Dahabieh, M. S., Nichol, J. N., Rincon, S. V. D., Gu, Y., Bohle, D. S., Sun, Y., Conklin, D. S., Mann, K. K., et al. (2014) · Molecular Pharmacology · doi:10.1124/mol.113.089433 · Cited by 35
“Introduction Arsenic trioxide (ATO) is a proven chemotherapy for acute promyelocytic leukemia (APL) (Shen et al., 1997; Soignet et al., 2001; Lo-Coco et al., 2008, 2013).”
BackgroundAdvances in acute myeloid leukemia differentiation therapy: A critical review
Abdel‐Aziz, A. K. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115709 · Cited by 37
Cull, E. H., & Altman, J. K. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-014-0205-6 · Cited by 31
Micol, J., Raffoux, E., Boissel, N., Lengliné, É., Canet, E., Daniel, M., de Labarthe, A., Maarek, O., Cassinat, B., Adès, L., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.023 · Cited by 31
“In addition, patients not fit for induction or consolidation CT received ATO considered to be the most effective single agent in APL with reduced therapy-related toxicity [11,36–38].”
BackgroundZhang, Y., Sun, M., Shi, W., Yang, Q., Chen, C., Wang, Z. P., & Zhou, X. H. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.11.028 · Cited by 33
Lou, Y., Ma, Y., Sun, J., Suo, S., Tong, H., Qian, W., Mai, W., Meng, H., & Jin, J. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3096-5 · Cited by 31
Liu, M., Zheng, B., Liu, P., Zhang, J., Chu, X., Dong, C., Shi, J., Liang, Y., Chu, L., Liu, Y., et al. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12077 · Cited by 32
Hamerschlak, N. (2016) · Medical Research Archives · doi:10.18103/mra.v4i7.755 · Cited by 31
Grochowska, K. M., Gomes, G. M., Raman, R., Kaushik, R., Sosulina, L., Kaneko, H., Oelschlegel, A. M., Yuanxiang, P., Reyes‐Resina, I., Bayraktar, G., et al. (2023) · The EMBO Journal · doi:10.15252/embj.2022112453 · Cited by 33
Iaccarino, L., Ottone, T., Divona, M., Cicconi, L., Cairoli, R., Voso, M. T., & Lo‐Coco, F. (2016) · British Journal of Haematology · doi:10.1111/bjh.13910 · Cited by 31
Self-citationRetinoid Signaling in Cancer and Its Promise for Therapy
Coyle, K. M. (2013) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.s7-006 · Cited by 36
“Most recently, atRA in combination with arsenic trioxide (As2O3), a second-line drug in the treatment of leukemias, has been used in treatment of APL by several groups with improved efficacy [188-190].”
BackgroundTechnical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia
Roloff, G. W., Lai, C., Hourigan, C. S., & Dillon, L. W. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6090087 · Cited by 36
“These assays serve only patients with favorable-risk disease, who represent only a minority of all AML cases [22,23].”
BackgroundAbdel‐Wahab, B. A., El‐Shoura, E. A. M., Habeeb, M. S., & Zaafar, D. K. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115794 · Cited by 30
All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia
Chen, Y., Tong, X., Lu, R., Zhang, Z., & Ma, T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1404092 · Cited by 39
Blagitko‐Dorfs, N., Jiang, Y., Duque‐Afonso, J., Hiller, J. K., Yalcin, A., Greve, G., Abdelkarim, M., Hackanson, B. W., & Lübbert, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075258 · Cited by 32
“acute myeloid leukemia [4], [5].”
Self-citationBeyond cisplatin: Combination therapy with arsenic trioxide
Miodragović, Ð., Swindell, E. P., Waxali, Z. S., Bogachkov, A., & O’Halloran, T. V. (2019) · Inorganica Chimica Acta · doi:10.1016/j.ica.2019.119030 · Cited by 33
When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia
Gurnari, C., Bellis, E. D., Divona, M., Ottone, T., Lavorgna, S., & Voso, M. T. (2019) · Chemotherapy · doi:10.1159/000507805 · Cited by 30
Self-citationWang, H., Zhang, L., Miao, Z., Zhang, M., Liu, H., He, Q., Meng, J., Wen, L., Ke, Z., Zha, Z., et al. (2021) · Materials Horizons · doi:10.1039/d0mh01992e · Cited by 32
Acute Myelogenous Leukemia and its Microenvironment: A Molecular Conversation
Ghiaur, G., Wroblewski, M., & Loges, S. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.03.003 · Cited by 34
Seftel, M. D., Barnett, M. J., Couban, S., Leber, B. F., Storring, J. M., Assaily, W., Fuerth, B., Christofides, A., & Schuh, A. C. (2014) · Current Oncology · doi:10.3747/co.21.2183 · Cited by 30
Zhou, N., Yao, Y., Ye, H., Zhu, W. P., Chen, L., & Mao, Y. Q. (2015) · International Journal of Cancer · doi:10.1002/ijc.29935 · Cited by 34
“Currently, retinoid use is hampered by its toxicity and the emergence of resistance.(17,18) It is desirable to develop and test ABAs that may exhibit similar anticancer activities with reduced side effects.”
BackgroundAccurate Drug Repositioning through Non-tissue-Specific Core Signatures from Cancer Transcriptomes
Chi, X., Ai, D., Shi, D., Suo, S., Chen, X., Yan, Y., Cao, Y., Zhang, R., Sun, N., Chen, W., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.031 · Cited by 32
Biomolecular phase separation in stress granule assembly and virus infection
Liu, Y., Yao, Z., Lian, G., & Yang, P. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023117 · Cited by 31
“Clinically, trioxide arsenite has been successfully used for acute promyelocytic leukemia (PML) treatment [44].”
BackgroundDecoding mitochondria's role in immunity and cancer therapy
Zhang, Y., YAN, H. H., Wei, Y., & Wei, X. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189107 · Cited by 33
Genomic Characterization of Acute Leukemias
Chiaretti, S., Gianfelici, V., Ceglie, G., & Foà, R. (2014) · Medical Principles and Practice · doi:10.1159/000362793 · Cited by 35
New treatment for acute myelogenous leukemia
Dinardo, C. D., & Cortes, J. E. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.981527 · Cited by 33
“individualized and targeted therapeutic approaches for genetically defined leukemia subgroups [12].”
BackgroundWampfler, J., Federzoni, E. A., Torbett, B. E., Fey, M. F., & Tschan, M. P. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.12.006 · Cited by 29
“Among others, PML-RARA causes a block in differentiation which can be nevertheless resolved with pharmaceutical doses of all-trans retinoic acid (ATRA).[15] The oncogenic fusion protein AML1-ETO is result of a translocation involving the genes AML1 on chromosome 8 and ETO on chromosome 21 present in the AML-M2 subtype.”
BackgroundMareschal, S., Palau, A., Lindberg, J., Ruminy, P., Nilsson, C. C., Bengtzén, S., Engvall, M., Eriksson, A., Neddermeyer, A., Marchand, V., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002517 · Cited by 35
Precision medicine in myeloid malignancies
Westermann, J., & Bullinger, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.034 · Cited by 30
3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
Tang, K., Schuh, A. C., & Yee, K. W. L. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01108-9 · Cited by 35
Identification of a c-MYB-directed therapeutic for acute myeloid leukemia
Clesham, K., Walf-Vorderwülbecke, V., Gasparoli, L., Virely, C., Cantilena, S., Tsakaneli, A., Inglott, S., Adams, S. P., Samarasinghe, S., Bartram, J. L., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01554-9 · Cited by 31
“…had spectacular success in specific subtypes of leukemia, exemplified by arsenic trioxide/all-trans retinoic acid induced degradation of the PML/RARA fusion protein in acute promyelocytic leukemia and imatinib inhibition of BCR/ABL fusion protein kinase activity in chronic myeloid leukemia [3, 4].”
Jiang, H., Liang, G., Huang, X., Jiang, Q., Han, S., Shi, L., & Zhu, H. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.09.007 · Cited by 30
Zhao, Y., Li, Y., LIU, B.-L., He, X., & ZHANG, B.-Y. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4367 · Cited by 29
“As 2 O 3 has been demonstrated to be effective in treating APL without significant side effects (8,9).”
Clonal evolution in therapy-related neoplasms
Fabiani, E., Falconi, G., Fianchi, L., Criscuolo, M., Ottone, T., Cicconi, L., Hohaus, S., Sica, S., Postorino, M., Neri, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14509 · Cited by 32
“The high curability of APL highlights the importance of avoiding genotoxic and mutagenic drugs in this disease, where chemotherapy-free regimens including arsenictrioxide have shown high curative potential at least in nonhigh risk patients [26].”
BackgroundSelf-citationTargeted therapy for fusion-driven high-risk acute leukemia
Pikman, Y., & Stegmaier, K. (2018) · Blood · doi:10.1182/blood-2018-04-784157 · Cited by 30
Platzbecker, U., Adès, L., Montesinos, P., Ammatuna, E., Fenaux, P., Baldus, C. D., Bernardi, M., Berthon, C., Bocchia, M., Bonmati, C., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00535 · Cited by 34
“9 10-12 However, few studies have examined the potential use of the chemo-free combination in the treatment of high-risk APL, which accounts for about 25% of all newly diagnosed APL cases.”
InfluentialSelf-citationEghtedar, A., Rodríguez, I., Kantarjian, H. M., O'Brien, S. M., Daver, N. G., Garcia‐Manero, G., Ferrajoli, A., Kadia, T. M., Pierce, S. A., Cortes, J. E., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.953143 · Cited by 28
Kuhn, K. D., Cott, C., Bohler, S., Aigal, S., Zheng, S., Villringer, S., Imberty, A., Claudinon, J., & Römer, W. (2015) · Cell Death Discovery · doi:10.1038/cddiscovery.2015.31 · Cited by 28
Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
Grimwade, D. J., Jovanovic, J. V., & Hills, R. K. (2014) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2014.04.002 · Cited by 28
“02) [26].”
BackgroundSwallowing a bitter pill–oral arsenic trioxide for acute promyelocytic leukemia
Torka, P., Ustwani, O. A., Wetzler, M., Wang, E. S., & Griffiths, E. A. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.11.004 · Cited by 29
“This activity against the LIC compartment may explain the marked clinical activity and low relapse rates observed with chemotherapy sparing differentiation therapy combining arsenic and ATRA [5,22].”
BackgroundThe Role of AMPK/mTOR Modulators in the Therapy of Acute Myeloid Leukemia
Višnjić, D., Dembitz, V., & Lalić, H. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180117105522 · Cited by 30
Burnett, A. K., & Grimwade, D. J. (2015) · Wiley eBooks · doi:10.1002/9781118853771.ch20 · Cited by 28
DNA Methylation Predicts the Response of Triple-Negative Breast Cancers to All-Trans Retinoic Acid
Coyle, K. M., Dean, C. A., Thomas, M. L., Vidovic, D., Giacomantonio, C. A., Helyer, L. K., & Marcato, P. (2018) · Cancers · doi:10.3390/cancers10110397 · Cited by 28
Outcomes in Adult Acute Promyelocytic Leukemia: A Decade Experience
Yedla, R. P., Bala, S. C., Pydi, V. R., Kuruva, S. P., Chennamaneni, R., Konatam, M. L., Paul, T. R., & Gundeti, S. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.12.011 · Cited by 27
Metadata
- Authors
- Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., Specchia, G., Sica, S., Divona, M., Levis, A., Fiedler, W., Cerqui, E., Breccia, M., Fioritoni, G., Salih, H. R., Cazzola, M., Melillo, L., Carella, A. M., Brandts, C. H., Morra, E., von Lilienfeld-Toal, M., Hertenstein, B., Wattad, M., Lübbert, M., Hänel, M., Schmitz, N., Link, H., Kropp, M. G., Rambaldi, A., La Nasa, G., Luppi, M., Ciceri, F., Finizio, O., Venditti, A., Fabbiano, F., Döhner, K., Sauer, M., Ganser, A., Amadori, S., Mandelli, F., Döhner, H., Ehninger, G., Schlenk, R. F., & Platzbecker, U.
- ORCID
- Avvisati, Giuseppe
- Vignetti, Marco
- Thiede, Christian
- Iacobelli, Simona
- Ferrara, Felicetto
- Fazi, Paola
- Cicconi, Laura
- Specchia, Giorgina
- Sica, Simona
- Fiedler, Walter
- Breccia, Massimo
- Salih, Helmut R.
- Cazzola, Mario
- Melillo, Lorella
- Carella, Angelo M.
- Brandts, Christian H.
- Hertenstein, Bernd
- Lübbert, Michael
- Hänel, Matthias
- Schmitz, Norbert
- Link, Hartmut
- Rambaldi, Alessandro
- Luppi, Mario
- Ciceri, Fabio
- Finizio, Olimpia
- Venditti, Adriano
- Döhner, Konstanze
- Ganser, Arnold
- Amadori, Sergio
- Döhner, Hartmut
- Ehninger, Gerhard
- Schlenk, Richard F.
- Platzbecker, Uwe
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-11
- Volume
- 369
- Issue
- 2
- Pages
- 111-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2129338773
- Cited by
- 1,611
- References
- 42
- Citations by year
- 2026: 83 · 2025: 89 · 2024: 132 · 2023: 144 · 2022: 110 · 2021: 147 · 2020: 137 · 2019: 125 · 2018: 122 · 2017: 107 · 2016: 117 · 2015: 144 · 2014: 119 · 2013: 33
- FWCI
- 61.62
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- acute promyelocytic leukemia, all-trans retinoic acid, arsenic trioxide, idarubicin, induction therapy, consolidation therapy, maintenance therapy, event-free survival, overall survival, complete remission, hematologic toxicity, hepatotoxicity
- MeSH terms
- Arsenic Trioxide, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Arsenicals, Female, Humans, Male, Middle Aged, Neutropenia, Oxides, Thrombocytopenia, Tretinoin, Leukemia, Promyelocytic, Acute, Disease-Free Survival, Young Adult, Maintenance Chemotherapy, Induction Chemotherapy, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.